---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000145"
form_type: "8-K"
ticker: "BBNX"
cik: "0001674632"
company_name: "Beta Bionics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:13:15.781592+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Beta Bionics preliminary Q4 2025 net sales ≥$32M, up >56% YoY; installed base >35K

## Summary
- Net sales expected ≥$32.0M, up >56% from $20.4M in Q4 2024.
- DME channel net sales ≥$22.3M (+23% YoY); PBP channel ≥$9.7M (+308% YoY).
- Installed customer base ≥35,000 users (+128% YoY); new patient starts ≥5,581 (+36% YoY).
- ~69% of new starts from multiple daily injections; 25-30% are type 2 diabetes patients.
- Full Q4 and FY 2025 results to be reported Feb 17, 2026; conference call scheduled.

## SEC filing metadata
- accession: 0001171843-26-000145
- form_type: 8-K
- ticker: BBNX
- cik: 0001674632
- company_name: Beta Bionics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674632/000117184326000145/0001171843-26-000145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674632/000117184326000145/f8k_010726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000145
- JSON: https://secwatch.observer/filing/0001171843-26-000145.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.